share_log

T2 Biosystems | 8-K: Entry into a Securities Purchase Agreement

T2 Biosystems | 8-K: Entry into a Securities Purchase Agreement

T2 Biosystems | 8-K：簽訂證券購買協議
美股sec公告 ·  05/20 19:05
牛牛AI助理已提取核心訊息
On May 14, 2024, T2 Biosystems, Inc., a Delaware-incorporated company, reported the entry into a Material Definitive Agreement with an institutional investor for a private placement. The agreement includes the sale of 1,700,000 shares of common stock, 325,317 pre-funded warrants, and series A and B warrants to purchase up to 2,025,317 shares each, generating gross proceeds of approximately $8.0 million. The pre-funded warrants and common warrants are immediately exercisable, with the series A warrants expiring five and a half years post-issuance and the series B warrants expiring 18 months post-issuance. The company also entered into a Registration Rights Agreement, obligating it to file a registration statement with the SEC by May 29, 2024, for the resale of the shares. Additionally, T2 Biosystems agreed to pay H...Show More
On May 14, 2024, T2 Biosystems, Inc., a Delaware-incorporated company, reported the entry into a Material Definitive Agreement with an institutional investor for a private placement. The agreement includes the sale of 1,700,000 shares of common stock, 325,317 pre-funded warrants, and series A and B warrants to purchase up to 2,025,317 shares each, generating gross proceeds of approximately $8.0 million. The pre-funded warrants and common warrants are immediately exercisable, with the series A warrants expiring five and a half years post-issuance and the series B warrants expiring 18 months post-issuance. The company also entered into a Registration Rights Agreement, obligating it to file a registration statement with the SEC by May 29, 2024, for the resale of the shares. Additionally, T2 Biosystems agreed to pay H.C. Wainwright & Co., LLC a cash fee and management fee totaling 8% of the gross proceeds, along with $85,000 for related expenses, and issued Wainwright designees warrants to purchase up to 141,772 shares of common stock. The securities sold in this private placement have not been registered under the Securities Act and were offered pursuant to an exemption from registration requirements.
2024年5月14日，特拉華州註冊成立的公司T2 Biosystems, Inc. 報告說，與一家機構投資者簽訂了私募的實質性最終協議。該協議包括出售1700,000股普通股、325,317份預先注資認股權證以及A系列和B系列認股權證，每份最多購買2,025,317股股票，總收益約爲800萬美元。預先注資的認股權證和普通認股權證可立即行使，A系列認股權證將在發行後五年半到期，B系列認股權證將在發行後18個月到期。該公司還簽訂了註冊權協議，要求其在2024年5月29日之前向美國證券交易委員會提交一份註冊聲明，以轉售股票。此外，T2 Biosystems同意向H.C. Wainwright & Co., LLC支付總收益的8％的現金費和管理費，以及8.5萬美元的相關費用，並向Wainwright指定人員發放了購買最多141,772股普通股的認股權證。本次私募中出售的證券尚未根據《證券法》註冊，是根據註冊要求豁免發行的。
2024年5月14日，特拉華州註冊成立的公司T2 Biosystems, Inc. 報告說，與一家機構投資者簽訂了私募的實質性最終協議。該協議包括出售1700,000股普通股、325,317份預先注資認股權證以及A系列和B系列認股權證，每份最多購買2,025,317股股票，總收益約爲800萬美元。預先注資的認股權證和普通認股權證可立即行使，A系列認股權證將在發行後五年半到期，B系列認股權證將在發行後18個月到期。該公司還簽訂了註冊權協議，要求其在2024年5月29日之前向美國證券交易委員會提交一份註冊聲明，以轉售股票。此外，T2 Biosystems同意向H.C. Wainwright & Co., LLC支付總收益的8％的現金費和管理費，以及8.5萬美元的相關費用，並向Wainwright指定人員發放了購買最多141,772股普通股的認股權證。本次私募中出售的證券尚未根據《證券法》註冊，是根據註冊要求豁免發行的。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

獨立文件6  查看翻譯

獨立文件7  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。